Inhaled treatment of COPD: a Delphi consensus statement by Ninane, Vincent et al.
© 2017 Ninane et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of COPD 2017:12 793–801
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
793
O r I g I n a l  r e s e a r C h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/COPD.S125564
Inhaled treatment of COPD: a Delphi consensus 
statement
Vincent ninane1
Jean-louis Corhay2
Paul germonpré3
Wim Janssens4
guy F Joos5
giuseppe liistro6
Walter Vincken7
sandra gurdain8
evelyne Vanvlasselaer8
an lehouck8
1Department of respiratory Medicine, 
saint-Pierre hospital, Université libre 
de Bruxelles, Brussels, 2Department 
of respiratory Medicine, ChU, 
liege, 3Department of respiratory 
Medicine, aZ Maria Middelares, 
ghent, 4Department of respiratory 
Medicine, Katholieke Universiteit, 
leuven, 5Department of respiratory 
Medicine, ghent University hospital, 
ghent, 6Department of respiratory 
Medicine, University hospitals 
saint-luc, Brussels, 7Department of 
respiratory Medicine, University 
hospital Brussels, Brussels, 8Medical 
Department, novartis Pharma, 
Vilvoorde, Belgium
Background: Global Initiative for Chronic Obstructive Lung Disease (GOLD) global strategy 
(2015) provides guidance for the treatment of chronic obstructive pulmonary disease (COPD) 
with different first-choice options per GOLD category without specification.
Objectives: To evaluate the level of medical experts’ consensus on their preferred first-choice 
treatment within different COPD categories.
Methods: A two-round Delphi Panel consisting of 15 questions was completed by Belgian 
pulmonologists (n=31) and European (n=10) COPD experts.
Results: Good consensus was reached by both expert groups for long-acting bronchodilators 
instead of short-acting bronchodilators as first-choice treatment in GOLD A. Single bronchodila-
tion with long-acting muscarinic antagonist (LAMA) was preferred over long-acting β2-agonist 
(LABA) and LABA/LAMA as first-choice treatment in GOLD B and GOLD C. For GOLD D 
patients based on the forced expiratory volume in 1 second (FEV
1
),50%, a very good con-
sensus was reached for LAMA/LABA as first-choice treatment. For GOLD D patients based 
on frequent or severe exacerbations, there was a good consensus for LABA/LAMA/inhaled 
corticosteroids (ICS) as first choice in the Belgian group. According to the European experts, 
both LABA/LAMA and LABA/LAMA/ICS could be the first choice for these patients.
Conclusion: Belgian and European experts recommend long-acting bronchodilators as 
first-choice treatment. Treatment containing ICS was found only appropriate in patients with 
FEV
1
,50% and $2 moderate exacerbations or 1 severe exacerbation/year.
Keywords: chronic obstructive pulmonary disease, therapy, long acting muscarinic antagonist, 
long acting beta agonist, inhaled corticosteroids, guidelines
Introduction
Chronic obstructive pulmonary disease (COPD) is defined as “a common preventable 
and treatable disease, characterized by persistent airflow limitation that is usually pro-
gressive and associated with an enhanced chronic inflammatory response in the airways 
and the lung to noxious particles or gases”.1 Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) global strategy has long recommended a stepwise approach 
in COPD management, based on the severity of airflow limitation. Bronchodilators 
are the mainstay treatment, and inhaled corticosteroids (ICS) can be added in case of 
frequent exacerbations.2 Stratification of patients according to the severity of COPD 
is important to initiate relevant treatment and is a crucial aspect of a management 
guideline. In the 2011 update of the GOLD global strategy, severity of symptoms 
(according to Modified Medical Research Council [mMRC] or COPD Assessment 
Test scores) and frequency of exacerbations were added next to lung function (forced 
expiratory volume in 1 second [FEV
1
]), as important parameters to take into account 
when recommending treatment.2 The main role of the new A–D classification is to 
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propose first-choice and alternative medical treatments for 
COPD patients within these groups.
For GOLD A patients, short-acting bronchodilation as 
needed is recommended as first-choice treatment. There is 
limited evidence to support recommendation of long-acting 
bronchodilation for this group of patients, because trials with 
long-acting bronchodilators have only been performed in 
patients with more severe airflow limitation.1
For GOLD B patients, treatment with a long-acting 
bronchodilator is recommended. There is no indication 
about whether to use a long-acting β2-agonist (LABA) or 
a long-acting muscarinic antagonist (LAMA). Although the 
GOLD global strategy states that combining bronchodilators 
of different pharmacological classes may improve efficacy 
and decrease the risk of side effects, there is no guidance on 
when to combine two bronchodilators.1
Patients belonging to GOLD C and D have been defined 
as those with a higher risk of disease progression, and 
first-choice treatments suggested for these patients include 
LAMA, LABA/ICS, or triple therapy (LABA/LAMA/ICS).1 
Knowing that GOLD C and D consist of patients with vari-
able lung function and a variable history of exacerbations, 
which is mirrored by quite distinct prognosis regarding risk 
of exacerbations and mortality, clear guidance is needed 
on first-choice treatment depending on patient characteris-
tics. There is, however, only one study directly comparing 
LAMA with LABA/ICS.3 Because of this lack of evidence, 
current GOLD global strategy gives no guidance on the first-
choice treatment for GOLD C and D patients.4 American 
Thoracic Society (ATS) and European Respiratory Society 
(ERS) confirm that numerous questions remain concerning 
the treatment of COPD in the ATS/ERS statement.5
Consensus methods, such as the Delphi process, can 
be useful in synthesizing many factors that guide clinical 
decision-making. This includes the evidence base and the 
many factors that often escape empirical study, such as 
feasibility, burden, and patient and clinician preference. 
Therefore, a Delphi Panel was conducted (among Belgian 
pulmonologists and European experts) to identify consensus 
on first-choice treatment for COPD patients, based on their 
airflow limitation, symptoms, history of exacerbations, and 
hospitalizations for an exacerbation.
Methods
study objectives
The objective of this Delphi Panel was to assess the level of 
consensus among the Belgian and European pulmonologists 
on the use of inhaled treatments in COPD subclasses. On the 
basis of GOLD 2015 classifications, different subgroups of 
COPD patients were created, according to the severity of 
airflow limitation, symptoms, history of exacerbations, and 
hospitalizations for an exacerbation.
The Delphi Panel
The Delphi Panel is a method for consensus-building using a 
questionnaire to collect data from a panel of experts.6 A major 
characteristic of the Delphi technique is the feedback process 
in which group responses obtained during one round are 
returned to the participants during the next round in the form 
of statistical summaries. This feedback process allows and 
encourages the participants to reassess their initial judgments 
provided in the previous round.
During several discussion sessions, the authors identi-
fied existing scientific evidence gaps regarding first-choice 
inhalation treatment for COPD and formulated 15 questions 
to poll expert opinion in these areas. A validation of this 
questionnaire was done by two external reviewers. The ques-
tionnaire included closed questions using the 11-point Likert 
scale, which is a 0- to 10-point scale, whereby 5 equals no 
difference. To identify the rationale of the treatment choice, 
open questions were added. The complete questionnaire can 
be found in the Supplementary materials.
The Delphi Panel was organized in two parallel 
groups: a Belgian group consisting of 35 Belgian COPD 
pulmonologists and a group of 11 COPD experts from 11 
different European countries were contacted. The Belgian 
participants were identified based on their local expertise 
in COPD. To represent the European consensus, 11 experts 
with scientific publications on the topic of COPD, from 11 
different European countries, were contacted. To allow for a 
comparison between local Belgian and European consensus, 
the data of both groups were analyzed separately.
The questionnaire was sent electronically to the partici-
pating physicians in two rounds. After the first round, group 
responses were analyzed and returned to the participants in 
the second round. In this second round, in addition to their 
individual responses and the group responses from the first 
round, they also received a sample of the experts’ rationales 
for each question. Rationales that were included in the second 
round were those rationales that were within the consensus 
range and were given by at least two participants in the first 
round. In this second round, participants were asked to adapt 
or confirm their previous answer based on the given informa-
tion in order to increase the consensus. After two rounds, the 
overall consensus was assessed.
The questionnaire comprised four patient categories, based on 
the current GOLD guidelines: COPD patients with FEV
1
$50%, 
not symptomatic (GOLD A); COPD patients with FEV
1
$50%, 
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symptomatic (GOLD B); COPD patients with FEV
1
,50%, but 
not symptomatic (GOLD C based on FEV
1
,50%); symptomatic 
COPD patients with either FEV
1
,50% and/or two exacerbations 
(requiring treatment with oral corticosteroids and/or antibiotics) 
and/or one hospitalization for an exacerbation in the previous 
12 months (GOLD D). No formal definition was used to cat-
egorize the patients as “symptomatic” or “not symptomatic” in 
this Delphi Panel. The decision was based on the participating 
physicians’ judgment. For each question, a set of predefined 
answers were provided at both ends of the 11-point Likert scale 
(Supplementary materials). As the aim of this Delphi Panel was 
to identify the participants’ preferred treatment options from an 
unbiased perspective, the participants were asked to answer the 
questions regardless of existing habits and applicable country-
specific reimbursement criteria or treatment recommendations.
As no patients or patient data were implicated at any 
point, the Saint-Pierre university hospital’s ethics committee 
approved the study and waived the requirement for patient 
written informed consent.
Data analysis
Only fully completed questionnaires were taken into account 
for data analysis. The data were analyzed using descriptive sta-
tistics and presented as median (Q2), quartiles, and interquartile 
range (Q1–Q3). The statistical analyses were performed using 
SPSS v.24 (IBM Corp., Armonk, NY, USA). The level of 
consensus (no consensus, some consensus, good consensus, 
and very good consensus) was based on the central tendency 
of the responses and the spread of the data (Table 1).7
Results
Thirty-five Belgian COPD pulmonologists and 11 European 
COPD experts were electronically contacted during the 
first round. Of these, 32 (94%) Belgian pulmonologists and 
11 (100%) European experts completed the first round of the 
Delphi Panel. Thirty-one (89%) Belgian pulmonologists and 
10 (91%) European COPD experts completed both rounds 
of the Delphi Panel. An overview of the central trends of the 
responses and the obtained consensus (no, some, good, or 
very good) are given in Table 2. The physician’s rationales 
can be found in Table S1.
COPD patients with FeV1$50%, not 
symptomatic (gOlD a)
A good consensus was reached by both Belgian and European 
experts to start therapy with long-acting instead of short-
acting bronchodilators for COPD patients with FEV
1
$50% 
who are not symptomatic (Table 2; question 1.1).
COPD patients with FeV1$50%, 
symptomatic (gOlD B)
For symptomatic COPD patients with FEV
1
$50%, start-
ing with single bronchodilation was preferred over dual 
bronchodilation with some consensus among Belgian experts 
and good consensus among European experts (Table 2; 
question 2.2). LAMA was preferred over LABA as a first-
choice treatment, with a good consensus among the Belgian 
experts and some consensus among the European experts. 
There was a very good consensus in both groups for treat-
ment with a combination of LABA/LAMA when a COPD 
patient with FEV
1
$50% remains symptomatic despite 
treatment with a single bronchodilator (LABA or LAMA; 
Table 2; questions 2.1–2.3).
When a COPD patient with FEV
1
$50% had one mod-
erate exacerbation in the previous 12 months despite treat-
ment with a LAMA, there was a very good consensus in the 
European group for treatment with a LABA/LAMA combi-
nation to be the best choice. In the Belgian group, however, 
there was only some consensus. When a COPD patient with 
FEV
1
$50% patient had one moderate exacerbation in the 
previous 12 months despite treatment with a LABA, a good 
consensus was reached in both groups for LABA/LAMA to 
be the best choice (Table 2; questions 2.4 and 2.5).
Both groups recommended with a good consensus that 
ICS should not be added to the treatment of a symptomatic 
patient with an FEV
1
$50% who had one moderate exacerba-
tion during the previous 12 months (Table 2; question 2.6).
COPD patient with FeV1,50%, but 
not symptomatic (gOlD C based on 
FeV1,50%)
A good consensus was reached in both groups for LAMA 
as a first-choice treatment for asymptomatic COPD patients 
with FEV
1
,50%. Both Belgian and European experts agreed 
Table 1 Definition of levels of consensus
Perfect 
consensus
all respondents agree on an answer
Very good 
consensus
Median and 50% of respondents at one integera or 
80% of respondents within one integer of the medianb
good 
consensus
50% of respondents within one integer of the median or 
80% of respondents within two integers of the median
some 
consensus
50% of respondents within two integers of the median or 
80% of respondents within three integers of the median
no consensus all other cases
Notes: adapted from Chest, 119, Baumann M, strange C, heffner J., Management 
of spontaneous pneumothorax an american College of Chest Physicians Delphi 
consensus statement, 590–602. Copyright (2001), with permission from elsevier.7 aFor 
example, median and 50% of respondents are both at 7 (integer = point on the likert 
scale); bFor example, median is 7 and 80% of respondents are between 6 and 8.
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Table 2 Central trends and degree of consensus reached after the second round
Group Q1 Median (Q2) Q3 Consensus
 1.1 Do you think it is useful to start therapy with long-acting bronchodilators in COPD patients with FeV1$50%, in the absence of symptoms?
0= nO; 10= Yes Be 6 7 8 good consensus
eU 2 8 8 good consensus
 2.1 If a symptomatic COPD patient with FeV1$50% is treated with one long-acting bronchodilator, what should be the first choice?
0= laBa; 10= laMa Be 5 7 8 good consensus
eU 5 8 10 some consensus
 2.2 What should be the first choice when treating a symptomatic COPD patient with FEV1$50%? single or dual bronchodilation?
0= laBa/laMa; 10= laBa/laMa Be 2 4 5 some consensus
eU 1 2 2 good consensus
 2.3 When a COPD patient with FeV1$50% remains symptomatic despite treatment with a single bronchodilator, a treatment with a combination of 
laBa/laMa is the best choice 
0= total disagreement; 10= complete agreement Be 8 9 10 Very good consensus
eU 10 10 10 Very good consensus
 2.4 When a COPD patient with FeV1$50% had one exacerbation (requiring treatment with oral corticosteroids and/or antibiotics, but no 
hospitalization) in the previous 12 months despite treatment with a laMa, a combination of laBa/laMa is the best choice
0= total disagreement; 10= complete agreement Be 3 5 7 some consensus
eU 8 9 10 Very good consensus
 2.5 When a COPD patient with FeV1$50% had one exacerbation (requiring treatment with oral corticosteroids and/or antibiotics, but no 
hospitalization) in the previous 12 months despite treatment with a laBa, a combination of laBa/laMa is the best choice
0= total disagreement; 10= complete agreement Be 5 7 8 good consensus
eU 7 8 10 good consensus
 2.6 When a COPD patient with FeV1$50% had one exacerbation (requiring treatment with oral corticosteroids and/or antibiotics, but no 
hospitalization) in the previous 12 months, an ICs should be added
0= total disagreement; 10= complete agreement Be 2 3 4 good consensus
eU 0 2 3 good consensus
 3.1 COPD patient with FeV1,50%, but not symptomatic. What should be the first choice when treating this patient? (0= total disagreement; 
10= complete agreement)
a) saBa/saMa Be 1 2 5 good consensus
eU 0 0 0 Very good consensus
b) laBa Be 3 6 7 good consensus
eU 1 1.5 4 some consensus
c) laMa Be 5 7 8 good consensus
eU 7 8 10 good consensus
d) laBa/ICs Be 0 1 3 good consensus
eU 0 0.5 2 good consensus
e) laBa/laMa Be 5 6 8 good consensus
eU 5 5 6 Very good consensus
f) laBa/laMa/ICs Be 0 1 2 Very good consensus
eU 0 0 3 Very good consensus
 4.1 What should be the first choice when treating a symptomatic COPD patient, with FEV1,50%, but no exacerbations in the previous 12 months? 
(0= total disagreement; 10= complete agreement)
a) laMa Be 5 6 8 some consensus
eU 0 5 10 no consensus
b) laBa/ICs Be 1 2 4 good consensus
eU 0 0.5 3 good consensus
c) laBa/laMa Be 7 8 9 Very good consensus
eU 8 9 10 Very good consensus
d) laBa/laMa/ICs Be 1 2 3 good consensus
eU 0 2 5 some consensus
 4.2 If the same patient, with FeV1,50%, but no exacerbations in the previous 12 months remains symptomatic after initial treatment with a laMa, 
what should be the most appropriate treatment? (0= total disagreement; 10= complete agreement)
a) laBa Be 1 2 2 good consensus
eU 0 0.5 2 good consensus
b) laBa/ICs Be 1 1 3 good consensus
eU 0 0.5 1 Very good consensus
c) laBa/laMa Be 9 9 10 Very good consensus
eU 10 10 10 Very good consensus
d) laBa/laMa/ICs Be 1 1 3 good consensus
eU 0 2 5 some consensus
(Continued)
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Table 2 (Continued)
Group Q1 Median (Q2) Q3 Consensus
 4.3 If the same patient, with FeV1,50%, but no exacerbations in the previous 12 months remains symptomatic after initial treatment with a laBa, 
what should be the most appropriate treatment? (0= total disagreement; 10= complete agreement)
a) laMa Be 3 4 5 good consensus
eU 0 0.5 4 good consensus
b) laBa/ICs Be 1 1 3 good consensus
eU 0 0.5 2 good consensus
c) laBa/laMa Be 8 9 10 Very good consensus
eU 10 10 10 Very good consensus
d) laBa/laMa/ICs Be 1 2 3 good consensus
eU 0 1.5 4 some consensus
 4.4 If a symptomatic COPD patient has an FeV1,50% but only one exacerbation (requiring treatment with oral corticosteroids and/or antibiotics, but 
no hospitalization) in the previous 12 months, what should be the first-choice treatment? (0= total disagreement; 10= complete agreement)
a) laMa Be 4 5 7 good consensus
eU 2 7.5 10 no consensus
b) laBa/ICs Be 1 2 4 good consensus
eU 0 0.5 2 good consensus
c) laBa/laMa Be 8 9 9 Very good consensus
eU 8 9 10 Very good consensus
d) laBa/laMa/ICs Be 2 3 5 good consensus
eU 0 0.5 4 good consensus
 4.5 If a COPD patient has an FeV1,50% and two exacerbations (requiring treatment with oral corticosteroids and/or antibiotics) or one hospitalization 
for an exacerbation in the previous 12 months, what should be the first-choice treatment? (0= total disagreement; 10= complete agreement)
a) laMa Be 2 3 5 good consensus
eU 0 0 3 Very good consensus
b) laBa/ICs Be 4 6 8 some consensus
eU 5 6 8 good consensus
c) laBa/laMa Be 4 5 7 good consensus
eU 6 8 8 good consensus
d) laBa/laMa/ICs Be 8 9 9 good consensus
eU 6 8 8 good consensus
 4.6 an ICs should always be added to the treatment if a COPD patient had two or more exacerbations (requiring treatment with oral 
corticosteroids and/or antibiotics, but no hospitalization) in the previous 12 months
(0= total disagreement; 10= complete agreement) Be 6 7 8 good consensus
eU 5 6.5 8 some consensus
 4.7 an ICs should always be added to the treatment if a COPD patient had an exacerbation requiring a hospitalization in the previous 12 months
(0= total disagreement; 10= complete agreement) Be 5 6 6 good consensus
eU 5 6 8 good consensus
Abbreviations: Be, Belgium pneumologists (n=31); COPD, chronic obstructive pulmonary disease; eU, european experts (n=10); FeV1, forced expiratory volume 
in 1 second; ICs, inhaled corticosteroids; laBa, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; Q1, first quartile; Q2, second quartile or median; 
Q3, third quartile.
that treatments containing ICS (LABA/ICS or LABA/
LAMA/ICS) are not an appropriate first-choice treatment in 
this category of patients (Table 2; question 3.1).
symptomatic COPD patients with either 
FeV1,50% and/or two exacerbations 
and/or one hospitalization for an 
exacerbation in the previous 12 months 
(gOlD D)
There was a very good consensus in both groups for LABA/
LAMA as a first-choice treatment for symptomatic COPD 
patients, with FEV
1
,50%, but no exacerbations in the 
previous 12 months. Most experts in both groups agreed 
that treatments containing ICS, either LABA/ICS or LABA/
LAMA/ICS, are not appropriate for patients with FEV
1
,50%, 
but no exacerbations in the previous 12 months (some and 
good consensus). If a COPD patient, with FEV
1
,50% but no 
exacerbations, remained symptomatic after treatment with a 
single bronchodilator, there was a very good consensus for 
LABA/LAMA being the best choice treatment. If the same 
patient had one moderate exacerbation (requiring treatment 
with oral corticosteroids and/or antibiotics, but no hospital-
ization) in the previous 12 months, there was a very good 
consensus for LABA/LAMA being the best choice treatment. 
Both groups agreed, with a good consensus, that treatments 
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containing ICS, either LABA/ICS or LABA/LAMA/ICS, 
are not appropriate for this category of patients (Table 2; 
questions 4.1–4.4).
A LABA/LAMA/ICS combination was recommended as 
a first-choice treatment by the Belgian experts, with a good 
consensus, for patients with FEV
1
,50% and two moderate 
or one severe exacerbation in the previous 12 months. In the 
European group, however, both LABA/LAMA and LABA/
LAMA/ICS were selected as first-choice treatments (Table 2; 
question 4.5).
In case of two or more moderate/severe exacerbations, 
there was a good consensus among Belgian and some con-
sensus among the European COPD experts to add an ICS to 
the treatment. In case of a hospitalization for an exacerbation, 
a good consensus but only a median score of 6 was reached 
by both Belgian and European groups to add an ICS to the 
treatment (Table 2; questions 4.6 and 4.7).
Discussion
A Delphi Panel was used to obtain consensus on the use of 
inhaled treatments in different COPD patient categories based 
on the level of symptoms, airflow obstruction, and exacerba-
tion history. This study, conducted among 31 Belgian and 
10 European COPD experts, showed a good consensus to 
start therapy with long-acting bronchodilators, regardless 
of symptoms. LAMAs were preferred over LABAs as a 
first-choice single bronchodilator. According to both Bel-
gian and European experts, dual bronchodilation should be 
preferred to single bronchodilation for treatment initiation in 
case of low FEV
1
 associated with symptoms with or without 
exacerbation history. ICS-containing treatments were only 
recommended for treatment initiation of patients with low 
FEV
1
 and symptoms, provided there was at least two moder-
ate or one severe exacerbation. Figure 1 gives an overview 
of European and Belgian experts’ consensus on first-choice 
treatment for COPD.
long-acting bronchodilation therapy as 
part of the maintenance treatment of all 
COPD patients
At least one long-acting bronchodilator was recommended 
by both Belgian and European experts for all the clinical 
conditions, and a good consensus was even reached for a 
long-acting bronchodilator as first-choice treatment in asymp-
tomatic patients with FEV
1
$50%. This is in contrast with 
the GOLD global strategy, which advises short-acting bron-
chodilators, as needed, as first-choice treatment for GOLD A 
patients, even if some COPD experts already recommended 
LABA or LAMA in benign diseases associated with low 
levels of symptoms and risks.1,8 This would, however, require 
further investigation because most studies with long-acting 
bronchodilators were performed with patients with more 
severe airflow limitation.9,10 Within the scope of the Delphi 
Panel, this choice was justified by the underestimation of 
symptoms by patients who may have already experienced 
reduced physical activity, as previously suggested by Pitta 
et al.11 In this respect, it is important to stress the lack of a 
gold standard to assess dyspnea.12 In clinical practice, mMRC 
is often used to assess dyspnea and its use is recommended in 
guidelines.1 There are, however, uncertainties about the cutoff 
(grade 2) used to define a high level of symptoms because 
recent studies suggest that mMRC grade 1 may already be 
associated with a significant impact.13 Recent data even 
suggest that some 50% of current or former smokers with 
preserved pulmonary function have respiratory symptoms 
that are associated with activity limitation and exacerbation 
risk and indeed, many of them already use bronchodilators.14 
Finally, subanalysis data of the UPLIFT study have dem-
onstrated a significant effect of tiotropium on lung function 
decline and disease progression in GOLD 2 patients and 
patients without maintenance treatment.15,16
laMas as preferred long-acting 
bronchodilators
For patients with FEV
1
$50%, results of this Delphi Panel 
demonstrated a preference for LAMA over LABA as a 
first-choice long-acting bronchodilator for both Belgian 
and European experts. This is supported by the better 
exacerbation-preventing effect of LAMA.17,18 For patients 
with FEV
1
,50%, without symptoms, there was a good 
consensus in both the Belgian and European groups for a 
LAMA as a first-choice treatment.
Treatment initiation with one single agent 
or immediate dual bronchodilation
With the introduction of fixed-dose dual-bronchodilation 
therapies, the question remains if treatment should be 
started with one single agent and then further stepped up if 
symptoms are not controlled or dual-bronchodilation therapy 
should be initiated immediately. According to the results 
of the Delphi Panel, Belgian and European experts sup-
port both strategies but in a different clinical context. They 
would start with one single agent, either LABA or LAMA, 
for symptomatic patients with FEV
1
$50% (GOLD B) and 
with dual bronchodilation for symptomatic patients with 
more severe airway obstruction (GOLD D). The European 
International Journal of COPD 2017:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
799
Inhaled treatment of COPD
experts justify starting with a single agent by the possibility 
to step up. For the Belgian experts, the choice to start with 
one single bronchodilator or dual bronchodilation would 
depend on the severity of airflow limitation. When a patient 
remains symptomatic, despite treatment with a single bron-
chodilator, or when the level of airflow obstruction is higher 
(FEV
1
#50%), and in case exacerbations are not frequent or 
severe, there was a very good consensus for LABA/LAMA 
combinations as first-choice treatments among both groups of 
experts. Better symptom control, maximum bronchodilation, 
and no need for ICS because of infrequent occurrence or mod-
erate severity of exacerbations were some of the rationales 
given to support this choice. However, LAMA/LABA as a 
first-choice treatment for patients with FEV
1
,50% is not in 
line with the current GOLD global strategy, which advises 
LAMA, LABA/ICS, or LABA/LAMA/ICS treatment for 
GOLD C–D patients, and LABA/LAMA combinations as 
alternative treatment options.1
Treatment containing ICs only 
appropriate for patients with FeV1,50% 
and frequent or severe exacerbations
Treatments containing ICS, either LABA/ICS or LABA/
LAMA/ICS, were only found to be an appropriate choice for 
patients with an FEV
1
,50% and two moderate or one severe 
exacerbation in the previous 12 months. Studies comparing 
dual bronchodilation with a fixed-dose LABA/ICS combi-
nation have shown superiority of dual bronchodilation on 
$
%
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Figure 1 Overview of expert’s consensus on first-choice treatment for COPD patients.
Notes: This figure gives a schematic overview of experts consensus on first-choice treatment for COPD patients with FEV1$50% (A) and FeV1,50% (B). *The preference 
for a laMa or a laBa was not investigated for patients with FeV1,50% who are not symptomatic. **according to the Belgian consensus, switch to laBa/laMa is only 
needed if patients have one exacerbation (requiring treatment with oral corticosteroids and/or antibiotics), despite treatment with a laBa, and not despite treatment with 
laMa. ***Belgian consensus was only reached for laBa/laMa/ICs; european consensus was reached for both laBa/laMa/ICs and laBa/laMa. 1Moderate exacerbation = 
exacerbations requiring treatment with oral corticosteroids and/or antibiotics in the previous 12 months. 2$2 moderate exacerbations or 1 severe exacerbation =$2 
exacerbations (requiring treatment with oral corticosteroids and/or antibiotics) or 1 hospitalization for an exacerbation in the previous 12 months.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in 1 second; ICs, inhaled corticosteroids; laBa, long-acting β2-agonist; 
laMa, long-acting muscarinic antagonist.
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lung function and dyspnea compared to LABA/ICS.19,20 The 
latter is further supported by the recently published FLAME 
study highlighting the superiority of LABA/LAMA over 
LABA/ICS on both lung function and exacerbations, for 
patients with a history of at least one exacerbation.21 The 
choice of adding an ICS on top of a dual-bronchodilation 
therapy depends, according to both Belgian and European 
experts, on the individual patient and potential risk of adverse 
events. Due to substantial adverse effects from the use of 
ICS in patients with COPD, the risk/benefit ratio of ICS 
should always be taken into account. The FLAME study 
demonstrated significantly more pneumonia in patients with 
a history of at least one exacerbation treated with LABA/ICS 
compared to LABA/LAMA.21 There is an urgent need for 
markers of benefit and risk that can be tested in randomized 
trials for use in routine specialist practice.22 Nevertheless, 
in contrast with the recommendation of the Delphi Panel, 
ICS have been used widely, with recent trials observing 
that .70% of COPD patients were treated with ICS at the 
time of enrollment. Evidence is mounting that such extensive 
use of ICS is discrepant with COPD treatment guidelines 
and may be inappropriate.23,24 Results of the WISDOM 
study, a step-down study from LABA/LAMA/ICS to dual 
bronchodilation, and the FLAME study that demonstrated 
a significant decrease of exacerbations with LABA/LAMA 
compared to LABA/ICS for patients with a history of at least 
one exacerbation question the absolute need of ICS for the 
prevention of exacerbations.25,21
strengths and limitations
The use of formal consensus techniques in medicine is 
becoming increasingly frequent. Consensus techniques such 
as the Delphi technique can be helpful in making decisions 
in situations where no gold standard exists or evidence is 
lacking. However, results of panel consensus judgment are 
only considered category D evidence according to GOLD 
2015 recommendations.1
The limitations of this study are 1) that the use of closed 
questions and multiple-choice questions may have limited 
responses or induced bias;26 2) although participants were 
instructed to complete the Delphi Panel regardless of current 
recommendations and reimbursement criteria, differences 
between the two groups may reflect geographically driven 
practices and biases. The fact that LAMA and LABA/
LAMA are subject to more restricted reimbursement criteria 
in Belgium compared with LABA and LABA/ICS could 
possibly explain the higher consensus scores for LABA for 
the Belgian compared to the European group.
Conclusion
This Delphi Panel answers some of the questions that 
remained unanswered in the GOLD global strategy. Few 
differences were observed between the European and 
Belgian experts in their respective consensus on the first-
choice treatment for COPD. Long-acting bronchodilators are 
recommended as a first-choice treatment for COPD patients 
without frequent and/or severe exacerbations, regardless of 
symptoms, with differences between Belgium pneumologists 
and European experts in the choice between LABA, LAMA, 
and LABA/LAMA. A very good consensus was reached in 
both groups to step up to LABA/LAMA when a single agent 
is not sufficient and for LABA/LAMA as a preferred first-
choice treatment over LABA/ICS for more severe patients 
with infrequent moderate exacerbations (#1 exacerbation). 
Treatment containing ICS was only found appropriate for 
patients with FEV
1
,50% and $2 moderate exacerbations 
or 1 severe exacerbation according to both Belgian and 
European experts.
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